Fubei Biotechnology

Fubei Biotechnology, also known as 4B Technologies, is a clinical-stage biotechnology firm concentrated on creating treatments for neurodegenerative diseases and neurological injuries. The company was registered in the Cayman Islands and Hong Kong in 2017 and became fully operational in 2018. Its preclinical research and development are centered in Suzhou, China, with clinical development teams in Beijing and Shanghai, and a business development unit in San Diego, California.

The company was founded by Dr. Bai Lu and Dr. Guan. Dr. Lu, who serves as Chairman of the Scientific Advisory Board, is a renowned neuroscientist with prior leadership roles at Tsinghua Medical School and GlaxoSmithKline R&D. His research has focused on neurodevelopment, synaptic plasticity, and nervous system diseases. Dr. Guan, the co-founder and President, has over 27 years of pharmaceutical R&D experience, primarily in central nervous system diseases, including a leadership position at GlaxoSmithKline and an 18-year tenure at Merck Research Labs.

4B Technologies operates on a business model that centers on advancing a portfolio of drug candidates through its pipeline, from discovery to clinical trials. The company's revenue generation will likely stem from strategic partnerships, licensing agreements with global pharmaceutical companies, and eventually, the commercialization of its own developed therapies. It has successfully raised a total of $39.1M through venture capital funding from investors including Fortune Capital, Gaorong Capital, and Zhongguancun Co-Innovation Fund. The firm's strategy involves addressing key challenges in CNS drug development by focusing on neuroprotection and controlling neuroinflammation, two common hallmarks of neurodegenerative diseases.

4B Technologies is developing a pipeline of first-in-class drug candidates. A key asset is 4B03-04, a humanized monoclonal antibody for chronic pain that works by selectively inhibiting pain signaling without the side effects associated with disrupting the nerve growth factor (NGF) pathway. This non-opioid therapy has shown a favorable safety profile in Phase 1 trials and is designed for a convenient monthly dosing schedule. Another significant candidate, 4B02-01, is an injectable drug for Amyotrophic Lateral Sclerosis (ALS) that activates the TrkB receptor to provide neuroprotective effects, building on over 20 years of research by Dr. Bai Lu. The pipeline also includes treatments for Glaucoma, Stroke, and Alzheimer's Disease (AD), employing various mechanisms such as CSF1R inhibitors to manage neuroinflammation. Keywords: neurodegenerative diseases, CNS drug discovery, biotechnology, neurological injuries, clinical-stage, ALS treatment, chronic pain therapy, monoclonal antibody, neuroinflammation, neuroprotection, TrkB agonist, CSF1R inhibitor, Alzheimer's research, Glaucoma treatment, Stroke therapy, venture capital-backed, Suzhou biotech, Bai Lu, Guan, drug development